Supernus Pharmaceuticals Bundle
Who owns Supernus Pharmaceuticals today?
Founded in 2005 by Jack A. Khattar and public since a 2012 IPO near $5 per share, Supernus shifted from founder-led to predominantly institutional ownership while commercializing CNS drugs like Oxtellar XR and Qelbree.
Ownership concentration—large institutional holders, board composition, and founder stakes—drives strategy, R&D priorities, and governance; recent shifts since 2021 affected voting power and activist interest. See Supernus Pharmaceuticals Porter's Five Forces Analysis.
Who Founded Supernus Pharmaceuticals?
Founders and early ownership of Supernus Pharmaceuticals trace to Jack A. Khattar, who spun drug‑delivery assets out of Shire in 2005 and led the privately held startup alongside early employees and aligned private investors focused on CNS formulation strategies.
Founder leadership
Jack A. Khattar served as founder and CEO, providing operational control and strategic direction from inception through IPO preparation.
Seed and growth capital
Early financings came from private investors and backers aligned with a CNS, formulation‑driven approach to build assets like Oxtellar XR and Trokendi XR.
Equity distribution
Detailed cap‑table percentages at formation were not publicly disclosed; the founder held a significant controlling position pre‑IPO with minority stakes for executives and investors.
Legal founder protections
Early agreements reportedly used standard founder vesting and buy‑sell provisions common in venture‑backed life‑science firms to retain key talent through milestones.
Broadened investor base
As late‑stage assets advanced, additional private financing expanded the equity base while preserving founder leadership ahead of the public offering.
Dispute history
No high‑profile founder disputes are publicly recorded; ownership distribution reflected Khattar’s operational control and long‑term CNS vision.
Early ownership set the stage for the company’s IPO and subsequent public ownership evolution; for context on competitors and market positioning see Competitors Landscape of Supernus Pharmaceuticals.
Key points on early ownership
Founding structure and investor dynamics that defined control and later public transition.
- Founder: Jack A. Khattar, former Shire Laboratories president.
- Private financings supported CNS, formulation strategy and late‑stage asset development.
- Founder retained significant pre‑IPO control; early execs and private backers held minority stakes.
- Standard vesting and buy‑sell provisions used to retain talent through clinical/regulatory milestones.
Supernus Pharmaceuticals SWOT Analysis
- Complete SWOT Breakdown
- Fully Customizable
- Editable in Excel & Word
- Professional Formatting
- Investor-Ready Format
How Has Supernus Pharmaceuticals’s Ownership Changed Over Time?
Key events shaping Supernus Pharmaceuticals ownership include the April 2012 IPO, commercialization milestones for Oxtellar XR and Trokendi XR (2013–2019), and the 2021–2024 strategic expansion including the Adamas acquisition and Qelbree approvals, which collectively shifted the cap table toward large institutional and passive holders.
| Period | Event | Ownership Impact |
|---|---|---|
| 2012 IPO | April 2012 offering ~ $5 per share; proceeds ~$50–$60M | Founder/early-holder dilution; mutual funds and hedge funds entered; initial market cap in low hundreds of millions |
| 2013–2019 Commercialization | Launch of Oxtellar XR and Trokendi XR | Attracted fundamental healthcare investors; passive ownership rose after Russell inclusion |
| 2021–2024 Expansion | Acquisition of Adamas (~$400M upfront + CVRs); Qelbree U.S. approvals | Increased institutional float; growth-focused and healthcare specialists retained interest |
As of latest SEC filings through 2024/early 2025, institutional ownership exceeds 90% of the public float, dominated by index and active managers; Vanguard and BlackRock are among the largest holders, each typically in the mid-to-high single-digit to low-double-digit percentage range, with Wellington, State Street and healthcare funds holding low-to-mid single digits; founder/CEO Jack A. Khattar is the largest individual insider at roughly mid-single-digit ownership.
Ownership Snapshot and Strategic Effects
Institutional concentration shapes governance and capital-allocation priorities, emphasizing buyback/M&A trade-offs and commercial execution for Qelbree and Gocovri.
- Who owns Supernus Pharmaceuticals: predominantly institutional investors and passive funds
- Supernus Pharmaceuticals ownership structure: >90% institutional ownership of float
- Supernus Pharmaceuticals major shareholders: Vanguard, BlackRock, Wellington, State Street (each usually low-to-mid double-digit/ single-digit ranges)
- Does Supernus Pharmaceuticals have a parent company or acquirer: no government or corporate parent; publicly traded standalone company
For more on strategic positioning and market approach, see Marketing Strategy of Supernus Pharmaceuticals
Supernus Pharmaceuticals PESTLE Analysis
- Covers All 6 PESTLE Categories
- No Research Needed – Save Hours of Work
- Built by Experts, Trusted by Consultants
- Instant Download, Ready to Use
- 100% Editable, Fully Customizable
Who Sits on Supernus Pharmaceuticals’s Board?
Supernus Pharmaceuticals’ board is chaired by founder, president, and CEO Jack A. Khattar and otherwise comprises a majority-independent slate with expertise in biopharma operations, R&D/clinical development, commercialization, and finance; several independents bring CNS/neurology and commercial scaling experience.
| Director / Role | Background | Independent? |
|---|---|---|
| Jack A. Khattar — Chair, President & CEO | Founder, executive leadership, commercial strategy | No |
| Independent Director — Biopharma Operations | Commercial scaling, manufacturing, operations | Yes |
| Independent Director — R&D / Clinical | CNS & neurology clinical development experience | Yes |
| Independent Director — Finance | Public company finance, audit committee experience | Yes |
The board maintains standard audit, compensation, and nominating/governance committees; no directors are publicly disclosed as representing a controlling shareholder and no dual-class or special voting shares exist.
Board and Voting Snapshot
The company uses a one-share-one-vote structure and governance is functionally dispersed across institutional holders and insiders; insider stakes are meaningful but not control-blocking as of 2024/2025.
- Single class common stock — one-share-one-vote; no dual-class or golden shares
- Insider ownership includes CEO and executive cohort; percentage ownership typically ranges in filings under 10–15% combined for top insiders (varies by latest 2024–2025 filings)
- Institutional investors and mutual funds hold significant voting power; no single institution publicly reported as majority holder
- No widely reported proxy contest or activist control battle through 2024/2025; shareholder focus on capital allocation, Qelbree and Gocovri execution, and late-stage regulatory clarity
For governance context and company purpose, see Mission, Vision & Core Values of Supernus Pharmaceuticals.
Supernus Pharmaceuticals Business Model Canvas
- Complete 9-Block Business Model Canvas
- Effortlessly Communicate Your Business Strategy
- Investor-Ready BMC Format
- 100% Editable and Customizable
- Clear and Structured Layout
What Recent Changes Have Shaped Supernus Pharmaceuticals’s Ownership Landscape?
Recent ownership trends at Supernus Pharmaceuticals show greater institutional concentration and modest insider dilution after the 2021–2022 Adamas acquisition; from 2023–2025 institutional ownership stayed above 90% while buybacks and earnings retention kept the share count roughly stable.
| Period | Key ownership change | Impact |
|---|---|---|
| 2021–2022 | Acquisition of Adamas (added Gocovri); float modestly increased; broader shareholder base | Revenue diversification; insider ownership diluted modestly vs 2010s |
| 2023–2025 | Institutional ownership > 90%; passive funds up after Russell rebalances; buyback authorizations | Stable to slightly reduced share count; signals confidence; continued founder-CEO leadership |
Institutional investor concentration mirrors mid-cap biopharma trends, drawing long-only healthcare funds rather than activists; management highlights balanced capital allocation across organic R&D, BD/M&A, and selective buybacks with no public plans for dual-class shares, go-private bids, or a controlling-stake sale as of 2025 — visit Target Market of Supernus Pharmaceuticals for related context.
Institutional concentration
By 2025, institutional investors held over 90% of the float; largest passive index funds and healthcare ETFs are primary holders.
Insider ownership
Insider stakes remain meaningful but diluted relative to 2010s levels; founder-CEO continuity preserves alignment without special voting rights.
Capital allocation
Management emphasizes a mix of organic pipeline spend, targeted M&A and opportunistic buybacks to manage dilution and support EPS.
Ownership risks
Concentration in large institutional holders reduces activist risk; steady commercial CNS cash flow attracts long-only healthcare funds rather than activists.
Supernus Pharmaceuticals Porter's Five Forces Analysis
- Covers All 5 Competitive Forces in Detail
- Structured for Consultants, Students, and Founders
- 100% Editable in Microsoft Word & Excel
- Instant Digital Download – Use Immediately
- Compatible with Mac & PC – Fully Unlocked
- What is Brief History of Supernus Pharmaceuticals Company?
- What is Competitive Landscape of Supernus Pharmaceuticals Company?
- What is Growth Strategy and Future Prospects of Supernus Pharmaceuticals Company?
- How Does Supernus Pharmaceuticals Company Work?
- What is Sales and Marketing Strategy of Supernus Pharmaceuticals Company?
- What are Mission Vision & Core Values of Supernus Pharmaceuticals Company?
- What is Customer Demographics and Target Market of Supernus Pharmaceuticals Company?
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.